Caris Life Sciences, Inc. 8-K

What Happened
Caris Life Sciences, Inc. announced its financial results for the quarter and fiscal year ended December 31, 2025 in a press release dated February 26, 2026. The company furnished that press release as Exhibit 99.1 to its Form 8-K. On the same date, Caris posted an update on its website reporting completion of the interim readout of Achieve 1, the study supporting the upcoming launch of its multi-cancer early detection (MCED) test, Caris Detect.

Key Details

• Press release announcing quarterly and full-year 2025 results issued and furnished to the SEC on February 26, 2026 (Exhibit 99.1).
• The financial results cover the quarter and year ended December 31, 2025.
• Company posted a website update (News & Events) about completion of the Achieve 1 interim readout related to Caris Detect (website content not incorporated into the 8-K).
• Form 8-K was signed by Luke Power, Senior VP, Chief Financial Officer and Chief Accounting Officer, dated February 26, 2026.

Why It Matters
This filing formally notifies investors that Caris has reported its latest quarterly and annual financial results and is advancing its Caris Detect MCED program with an Achieve 1 interim readout—an operational milestone tied to commercialization plans. Investors should review the press release (Exhibit 99.1) and the website update for the specific financial figures and any commentary on business outlook or timing for Caris Detect launch. Note the filing states the furnished materials are not deemed “filed” under Section 18 of the Exchange Act.